Role of telomeres and telomerase in genomic instability, senescence and cancer

Laboratory Investigation

Volumn 87, Issue 11, 2007, Pages 1071-1076

  Deng, Yibin ^a   Chang, Sandy ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

DNA damage; Genomic instability; Replicative senescence; Telomeres; Tumorigenesis

Indexed keywords

CANCER VACCINE; DNA; DOUBLE STRANDED DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRN 163 L; GV 1001; HR 2822; OLIGONUCLEOTIDE; PROTEIN P53; RIBONUCLEOPROTEIN; TELOMERASE; UNCLASSIFIED DRUG;

APOPTOSIS; BONE MARROW TOXICITY; CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CARCINOMA; CELL AGING; CHROMOSOMAL INSTABILITY; CHROMOSOME; CHROMOSOME STRUCTURE; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME REGULATION; GENOMIC INSTABILITY; GLIOBLASTOMA; HEMATOMA; HUMAN; LUNG SMALL CELL CANCER; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE; TELOMERE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 35348958935     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700673     Document Type: Review

References (50)

1. Henderson BE, Bernstein L. Endogenous and exogenous hormonal factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds). Diseases of the Breast. Lippincott-Raven: Philadelphia, 1996.
2. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogensis. Br J Cancer 1954;8:1-12.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
4. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-3079.
5. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392:300-303.
6. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
7. Keohavong P, Gao W, Madhy H, et al. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett 2004;212:121-130.
8. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-2110.
9. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
10. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992;89:10114-11018.
11. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-636.
12. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-9367.
13. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanisms? Trends Cell Biol 1995;5:293-297.
14. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-522.
15. Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-295.
16. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA [see comments]. Cell 1997;91:25-34.
17. Greenberg RA, Chin L, Femino A, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999;97:515-525.
18. Gonzalez-Suarez E, Samper E, Flores I, et al. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Gen 2006;26:114-117.
19. Cosme-Blanco W, Shen S, Lazar A, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by activating p53-mediated cellular senescence. EMBO Reports 2007;8:497-503.
20. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007;11:461-469.
21. Sedivy JM. Telomeres limit cancer growth by inducing senescence: long-sought in vivo evidence obtained. Cancer Cell 2007;11:389-391.
22. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
23. Beausejour CM, Krtolica A, Gamlimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003;22:4212-4222.
24. Sage J, Miller AL, Perez-Mancera PA, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003;424:223-228.
25. Krtolica A, Parrinello S, Lockett S, et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001;98:12072-12077.
26. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-1929.
27. Chang S, Khoo C, Naylor M, et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes and Development 2003;17:88-100.
28. Shay JW, Van Der Haegen BA, Ying Y, et al. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 1993;209:45-52.
29. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-352.
30. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-282.
31. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
32. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
33. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-1274.
34. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
35. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
36. Veloso M, Wrba F, Kaserer K, et al. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer. Virchows Arch 2000;437:241-247.
37. Artandi S, Chang S, Lee S, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
38. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002;2:149-155.
39. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007;447:966-971.
40. Chin K, de Solorzano CO, Knowles A, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004;36:984-988.
41. Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 2004;9:285-296.
42. Tsao JL, Zhao Y, Lukas J, et al. Telomerase activity in normal and neoplastic breast. Clin Cancer Res 1997;3:627-631.
43. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577-584.
44. Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 2006;6:1031-1039.
45. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunotherapy 2006;55:1553-1564.
46. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474-1482.
47. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005;65:7866-7873.
48. Jackson SR, Zhu CH, Paulson V, et al. Antiadhesive effects of GRN163L - an Oligonucleotide N3′→P5′ Thio-Phosphoramidate targeting Telomerase. Cancer Res 2007;67:1121-1129.
49. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2006;42:1127-1136.
50. Ozawa T, Gryaznov SM, Hu LJ, et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-oncol 2004;6:218-226.